The Supreme Court will rule this term on whether EPA's Roundup label approval under FIFRA preempts state cancer-warning claims, threatening 60,000 active suits.
The Supreme Court heard oral arguments April 27 on a question that will determine the fate of tens of thousands of personal-injury claims against Bayer AG and its subsidiary Monsanto: whether the Environmental Protection Agency's approval of Roundup's label under the Federal Insecticide, Fungicide, and Rodenticide Act preempts state-law failure-to-warn claims alleging the herbicide's active ingredient, glyphosate, causes cancer [1]. A decision is expected before the current term closes, likely in late June [2]. The stakes are categorical. A ruling for Bayer could extinguish roughly 60,000 active claims in a stroke; a ruling for plaintiffs removes what litigants and observers have characterized as the company's primary legal shield against continuing mass-tort exposure [1].
The case arrives at the Court after years of sprawling federal multidistrict litigation centered in the Northern District of California, where Bayer has already paid billions to resolve earlier waves of claims. The core preemption argument is structural: FIFRA requires manufacturers to obtain EPA approval for pesticide labeling, and Bayer contends that a state-law duty to warn, requiring language the EPA never mandated, directly conflicts with and is therefore displaced by that federal regulatory scheme [1]. Plaintiffs counter that FIFRA's express preemption clause is narrow, and that state tort law can coexist with federal labeling requirements without frustrating congressional intent [2].
The preemption question carries significance well beyond Roundup. A broad ruling for Bayer could reset the boundary between federal pesticide regulation and state products-liability law across the agricultural and consumer-products industries, insulating manufacturers from state-court failure-to-warn claims whenever a federal agency has affirmatively reviewed and approved a label. A narrow ruling, or one favoring plaintiffs, would reaffirm that federal regulatory approval does not categorically foreclose state tort remedies, preserving a litigation pathway used across numerous product-liability dockets [1].
The outcome will also determine the practical viability of a pending $7.25 billion class settlement that Bayer has negotiated with remaining claimants [1]. If preemption carries the day, Bayer's incentive to fund any settlement diminishes sharply. If the Court rules for plaintiffs, Bayer faces sustained MDL litigation with no federal escape hatch and renewed pressure to finalize settlement terms. Counsel on both sides, and the MDL court, are now holding position pending the ruling [2]. The legal and financial exposure riding on a single term-end opinion makes this among the most consequential product-liability decisions in years.